Main methodological aspects of determining the chewing efficiency

Abstract

Heart failure is one of the most urgent problems of medicine, because the number of patients suffering from this pathology continues to grow steadily. The arsenal of drugs for the treatment of chronic heart failure has been replenished with new samples that have demonstrated significant effectiveness in improving the course and prognosis of patients in this cohort. However, the search for other promising drugs continues. The aim of our work is to summarize existing scientific data on the effect of sodium-glucose cotransporter-2 inhibitors, vericiguat, omecamtiv mecarbil on the clinical course and prognosis in patients with chronic heart failure, as well as the analysis of current clinical studies aimed at evaluating hemodynamic effects, tolerability and safety of experimental drugs in patients with chronic heart failure. The positive effects of sodium-glucose cotransporter-2 inhibitors have led to their inclusion in European guidelines for treating patients with chronic heart failure, regardless of left ventricular ejection fraction. Vericiguat is recommended for patients with NYHA class II-IV chronic heart failure and reduced left ventricular ejection fraction who have decompensated heart failure within the past 3 months despite receiving optimal chronic heart failure therapy. Omecamtiv mecarbil has been considered a promising drug for the treatment of heart failure due to its ability to reduce the primary composite endpoint compared to placebo for many years. However, in 2023, the US Food and Drug Administration refused to approve omecamtiv mecarbil for the treatment of adult heart failure patients with reduced left ventricular ejection fraction, citing insufficient evidence of the drug’s effectiveness. Development of new drugs for patients with chronic heart failure opens up new opportunities to improve the quality of life and prognosis of patients. Ongoing clinical trials of experimental drugs give hope for breakthrough results.